adar poonawalla on serum's $ 300 m investment in biocon biologics | trading hour | cnbc-tv18
Published 1 year ago • 1.7K plays • Length 19:14
Download video MP4
Download video MP3
Similar videos
-
5:24
serum takes its investment in biocon bio to $300 million, kiran m shaw on this & more | cnbc-tv18
-
9:09
confident that issues at malaysian plant will be behind once it is inspected: biocon biologics
-
6:56
biocon biologics restructures deal with sii | nithya balasubramanian speaks on this & more
-
0:31
adar poonawalla ceo of serum institute acquires london's priciest mansion of 2023 at ₹1,446 cr n18s
-
8:21
biocon biologics: net profit zoom 550%, what is companies growth plan for fy25? | siddharth mitthal
-
7:07
textile industry is facing issues, weak exports, geopolitics weigh: birla sugar | cnbc tv18
-
5:58
injection moulding will improve as utilisation will scale up: cosmo first | cnbc tv18
-
24:15
spotlight on biocon-serum deal, ipca's unichem acquisitions & mankind pharma's ipo | cnbc-tv18
-
2:35
strong biosimilar growth powers biocon | trading hour | cnbc tv18
-
11:03
key stocks in focus: eicher motors, abb, biocon, lic, concor, oil india, sail, mcx, cochin shipyard
-
4:54
what are the key stocks & sectors in focus today? | cnbc tv18
-
6:50
biocon's kiran mazumdar shaw on strong q4, biosimilar business & fy24 outlook | halftime report
-
4:47
biocon biologics' shreehas tambe speaks on the firm's deal with japan's yoshindo | cnbc-tv18
-
5:20
adar poonawalla on serum institute of india's focus on tb & malaria vaccines | davos 2023 |cnbc-tv18
-
2:29
adar poonawalla: india's image as the pharmacy of the world is very strong | ibla | cnbc-tv18
-
2:08
biocon biologics is well-placed to take advantage of opportunities in the biosimilars space: ceo
-
23:38
spotlight on stock market highlights, serum's biocon bet, nestle india's q4 earnings & many more
-
4:33
biocon biologics's shreehas tambe speaks on us fda's observation | bazaar open exchange | cnbc-tv18
-
7:50
kiran mazumdar shaw shares her views on biocon biologics acquiring viatris biosimilar's business
-
7:01
biocon q3 net profit falls 25%, revenue jumps 36%: kiran mazumdar shaw exclusive | cnbc-tv18
-
11:22
insulin aspart & bevacizumab have seen approvals across markets globally: biocon biologics
-
14:33
bit cautious at this stage, market has to absorb a lot of negative global news: enam’s sivaram
Clip.africa.com - Privacy-policy